medigraphic.com
SPANISH

Salud Pública de México

Instituto Nacional de Salud Pública
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Authors instructions        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2015, Number 2

salud publica mex 2015; 57 (2)

Primary drug resistance in a region with high burden of tuberculosis. A critical problem

Villa-Rosas C, Laniado-Laborín R, Oceguera-Palao L
Full text How to cite this article

Language: English
References: 10
Page: 177-179
PDF size: 231.93 Kb.


Key words:

treatment outcome, resistance amplification, isoniazid, rifampin.

ABSTRACT

Objective. To determine rates of drug resistance in new cases of pulmonary tuberculosis in a region with a high burden of the disease. Materials and methods. New case suspects were referred for drug susceptibility testing. Results. 28.9% of new cases were resistant to at least one first line drug; 3.9% had a multidrug-resistant strain, 15.6% a monoresistant strain and 9.4% a polyresistant strain. Conclusion. Our rate of drug resistant tuberculosis in new cases is very high; this has important clinical implications, since even monoresistance can have a negative impact on the outcome of new cases treated empirically with a six month regimen.


REFERENCES

  1. Yee DP, Menzies D, Brassard P. Clinical outcomes of pyrazinamidemonoresistant Mycobacterium tuberculosis in Quebec. Int J Tuberc Lung Dis 2012;16:604-609.

  2. Gegia M, Cohen T, Kalandadze I, Vashakidze L, Furin J. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009. Int J Tuberc Lung Dis 2012;16:812-816.

  3. Dantes R, Metcalfe J, Kim E, Kato-Maeda M, Hopewell PC, Kawamura M, et al. Impact of isoniazid resistance-conferring mutations on the clinical presentation of isoniazid monoresistant tuberculosis. PLoS ONE 2012;7:e37956. doi:10.1371/journal.pone.0037956.

  4. Seung KJ, Gelmanova IE, Peremitin GG, Golubchikova VT, Pavlova VE, Sirotkina OB, et al. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. Clin Infect Dis 2004;39:1321-1328.

  5. Instituto Nacional de Estadística, Geografía e Informática. Número de habitantes [online monograph]. México: Inegi, 2014. [accessed on 2014 December 17]. Aviable at: http://cuentame.inegi.org.mx/monografias/informacion/ bc/poblacion/

  6. World Health Organization. Treatment of tuberculosis: guidelines–4th ed WHO/HTM/TB/2009.420. Geneva: WHO, 2009: 420.

  7. Menzies D, Benedetti A, Paydar A, Royce S, Pai M, Burman W, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009;6:e1000150. doi:10.1371/journal. pmed.1000150.

  8. World Health Organization. Guidelines for the programmatic management of drug-resistant TB: emergency update 2008. Geneva, Switzerland: WHO, 2008.

  9. Curry International Tuberculosis Center and California Department of Public Health. Drug-resistant tuberculosis: a survival guide for clinicians. 2nd ed. San Francisco, California: University of California, 2011:33.

  10. Grzybowski S, Enarson D. The fate of cases of pulmonary tuberculosis under various treatment programmes. Bull Int Union Tuberc Lung Dis 1978;53:70-75.




2020     |     www.medigraphic.com

Mi perfil

CÓMO CITAR (Vancouver)

salud publica mex. 2015;57